CEACAM5 and prostate carcinoma: We next assessed the cytotoxicity of our anti-CEACAM5 CAR-T cells for DM4S NSCLCs and PDACs in vitro. Our anti-CEACAM5 CAR-T cells were previously generated and evaluated in prostate cancer cells in vitro and in vivo (35).